Neurology Alert – September 1, 2012
September 1, 2012
View Issues
-
Can We Predict Pharmacoresistant Epilepsy?
In this long-term, population-based patient series, the authors explore the natural course of drug-resistant epilepsy and explore whether remission can be predicted by clinical features. -
Antioxidant Supplements Are Not of Proven Benefit for Alzheimer's Disease
In this well-designed, randomized, placebo-controlled clinical trial of antioxidant supplements for Alzheimer's disease, there was no benefit, and some agents were associated with worse outcome. -
Alternate Day Steroids for Polymyositis
An alternate-day steroid protocol appears to be just as efficacious as every-day steroids over the long term in a group of patients with undifferentiated polymyositis, with less serious long-term side effects. -
Frontostriatal Network Under-recruitment Underlies Mild Cognitive Impairment in Parkinson's Disease
Multimodal brain imaging demonstrates extensive frontostriatal dysfunction in mild cognitive impairment in early Parkinson's disease. -
More Than Just a Number: Complexity of Intracranial Pressure Correlates with Outcome After Traumatic Brain Injury
Analysis of intracranial pressure complexity using a non-linear method of multiscale entropy shows that it correlates with outcome after traumatic brain injury. -
Mesenchymal Stem Cells Therapy for Multiple System Atrophy
Mesenchymal stem cells for the treatment of multiple system atrophy is a promising potential therapy, but requires further investigation regarding both safety and efficacy. -
Pharmacology Watch: Does Finasteride Cause Permanent Sexual Side Effects?
Side effects of finasteride; new ruling on pharmaceutical companies paying generic manufacturers; and FDA actions. -
Clinical Briefs in Primary Care Supplement